Latest Breaking News On - Pharma limited nasdaq - Page 3 : comparemela.com

OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule

OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomGarys jacobPaul spencerPharma limited nasdaqListing qualifications departmentNasdaq stock marketNasdaq capital marketNasdaq listing ruleChief executiveAktien sie

OKYO Pharma Limited Announces Withdrawal of Public Offering

OKYO Pharma Limited Announces Withdrawal of Public Offering
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomGary jacobPaul spencerGarys jacobPharma limited nasdaqChief executiveAktien sie

OKYO Pharma Limited Receives Nasdaq Deficiency Notice

OKYO Pharma Limited Receives Nasdaq Deficiency Notice
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Paul spencerGarys jacobNasdaq listing qualifications panel thePharma limited nasdaqListing qualifications departmentNasdaq stock marketNasdaq capital marketNasdaq listing ruleNasdaq capitalMarket valueCompliance dateCompliance period ruleMarket value ruleNasdaq listing qualifications panelChief executive

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesCity ofUnited kingdomGarys jacobPaul spencerPharma limited nasdaqExchange commissionChief executive

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (NCP) Following Announcement of Clinical Trial Agreement with Tufts Medical Center

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (NCP) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomPaul spencerGarys jacobPedram hamrahTufts medical centerTranslational ocular immunology at tufts medical centerCornea servicePharma limited nasdaqPrincipal investigatorInvestigational new drugVice chairAcademic programsTranslational ocular immunologyTufts medicalAdvisory board